Certara to Sell Regulatory Business for $135M

By Chris Stiles • Wednesday, April 22 10:32 • Permanent Link

Certara has agreed to sell its regulatory and medical writing business to Veristat for as much as $135 million, a move that will strip out a unit that produced $50 million in revenue and $17 million in adjusted EBITDA in 2025.

The business being sold employs about 220 people. Certara said the transaction is expected to close in the second quarter of 2026, after which it plans to update its full-year 2026 guidance to reflect the divestiture.

The sale marks a sharper concentration on Certara’s model-informed drug development and clinical intelligence businesses. Chief Executive Jon Resnick said the deal is intended to accelerate investment in its integrated MIDD platform and AI-enabled modeling and simulation capabilities.

Certara said the transaction comes as it looks to deploy the proceeds to support long-term value creation. The company did not say how much of the $135 million consideration would be paid at closing versus later. As a result of these announcements, the company's shares have moved 0.66% on the market, and are now trading at a price of $6.14. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.